|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan显示文摘AIM:To evaluate the efficacy of pegylated interferon α-2b(peg-IFNα-2b) plus ribavirin(RBV) therapy in Japanese patients with chronic hepatitis C(CHC) genotype Ib and a high viral load.METHODS:One hundred and twenty CHC patients(58.3% male) who received peg-IFNα-2b plus RBV therapy for 48 wk were enrolled.Sustained virological response(SVR) and clinical parameters were evaluated.RESULTS:One hundred(83.3%) of 120 patients completed 48 wk of treatment.53 patients(44.3%) achieved SVR.Early virological response(EVR) and end of treatment response(ETR) rates were 50% and 73.3%,respectively.The clinical parameters(SVR vs non-SVR) associated with SVR,ALT(108.4 IU/L vs 74.5 IU/L,P = 0.063),EVR(76.4% vs 16.4%,P < 0.0001),adherence to peg-IFN(≥ 80% of planned dose) at week 12(48.1% vs 13.6%,P = 0.00036),adherence to peg-IFN at week 48(54.7% vs 16.2%,P < 0.0001) and adherence to RBV at week 48(56.1% vs 32.1%,P = 0.0102) were determined using univariate analysis,and EVR and adherence to peg-IFN at week 48 were determined using multivariate analysis.In the older patient group(> 56 years),SVR in females was significantly lower than that in males(17% vs 50%,P = 0.0262).EVR and adherence to Peg-IFN were demonstrated to be the main factors associated with SVR.CONCLUSION:Peg-IFNα-2b plus RBV combination therapy demonstrated good tolerability in Japanese patients with CHC and resulted in a SVR rate of 44.3%.Treatment of elderly female patients is still challenging and maintenance of adherence to peg-IFNα-2b is important in improving the SVR rate. | Takayuki Kogure Yoshiyuki Ueno Koji Fukushima Futoshi Nagasaki Yasuteru Kondo Jun Inoue Yasunori Matsuda Eiji Kakazu Takeshi Yamamoto Hiroyoshi Onodera Yutaka Miyazaki Hiromasa Okamoto Takehiro Akahane Tomoo Kobayashi Yutaka Mano Takao Iwasaki Motoyasu Ishii Tooru Shimosegawa | 2008 | World Journal of Gastroenterology2008，14，47： | 7 |
| 2 | MK-0626,a selective DPP-4 inhibitor,attenuates hepatic steatosis in ob/ob mice显示文摘AIM:To investigate the mechanism and in vivo effects of MK-0626,a dipeptidyl peptidase-4 inhibitor,on hepatic steatosis using ob/ob mice.METHODS:We analyzed obese(ob/ob)8-wk-old male mice that had been randomly divided into two groups of ob/ob mice(n=16 each)and were treated with1.5 or 3 mg/kg MK-0626 and two control groups of untreated ob/ob mice and lean littermates(n=16 each).All mice were fed a normal chow diet with or without MK-0626 for either four or eight weeks.Blood samples were collected,and total hepatectomy was performed.RESULTS:The administration of dietary MK-0626 ameliorated the hepatic lipid accumulation in ob/ob micetreated with 3 mg/kg MK-0626(3 MK),P<0.05,vs untreated ob/ob mice(ob/ob).The MK-0626 treatment reduced the serum alanine aminotransferase levels(both treatment groups,P<0.05 vs ob/ob)and glucoses/insulin levels/calculated HOMA scores(1.5 MK,P<0.05vs ob/ob;3 MK,P<0.01 vs ob/ob)and increased the serum adiponectin levels(3 MK,P<0.05 vs ob/ob)in a dose-dependent manner.The MK-0626 treatment increased the m RNA expression of peroxisome proliferator-activated receptorα/microsomal triglyceride transfer protein(1.5 MK,P<0.05 vs ob/ob;3 MK,P<0.01vs ob/ob)but reduced the sterol regulatory element binding transcription factor-1c/fatty acid synthase/stearoyl-Co A desaturase-1(both treatment groups,P<0.01 vs ob/ob).The MK-0626 treatment increased the activity of AMP-activated protein kinase(AMPK)(both treatment groups,P<0.01 vs ob/ob).CONCLUSION:MK-0626 could attenuate hepatic steatosis through enhancing AMPK activity,inhibiting hepatic lipogenic gene expression,enhancing triglyceride secretion from liver and increasing serum adiponectin levels. | Tatsuya Ohyama Ken Sato Yuichi Yamazaki Hiroaki Hashizume Norio Horiguchi Satoru Kakizaki Masatomo Mori Motoyasu Kusano Masanobu Yamada | 2014 | World Journal of Gastroenterology2014，20，43： | 4 |
| 3 | Development and evaluation of FSSG: frequency scale for the symptoms of GERD显示文摘 | Motoyasu Kusano Yasuyuki Shimoyama Sayaka Sugimoto Osamu Kawamura Masaki Maeda Keiko Minashi Shiko Kuribayashi Tatsuya Higuchi Hiroaki Zai Kyoko Ino Tsutomu Horikoshi Tadashi Sugiyama Munetoshi Toki Tsuneo Ohwada Masatomo Mori | 2004 | Journal of Gastroenterology2004，，9： | 2 |
| 4 | A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis显示文摘 | Shuichi Ohara Ken Haruma Yoshikazu Kinoshita Motoyasu Kusano | 2010 | Journal of Gastroenterology2010，，12： | 2 |
| 5 | Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus显示文摘The standard antiviral therapy for dialysis patients infected with hepatitis C virus(HCV) is(pegylated) interferon monotherapy, but its efficacy is insufficient. Oral direct-acting antiviral agents(DAAs) have recently been developed for chronic hepatitis C patients. However, some DAAs have contraindications for chronic renal failure(CRF). Daclatasvir and asunaprevir are metabolized largely in the liver and are not contraindicated in CRF. Combination therapy with daclatasvir and asunaprevir was used for 4 dialysis patients infected with genotype 1b HCV. One patient had viral breakthrough, and the 3 others had sustained virological response 12. One patient was admitted for heart failure and percutaneous coronary intervention due to concomitant ischemic disease. Heart failure was unlikely to be caused by the combination therapy, as it was probably due to water overload. The patient continued to receive the combination therapy after the remission of the heart failure. The combination therapy was well tolerated in the other patients. | Ken Sato Yuichi Yamazaki Tatsuya Ohyama Takeshi Kobayashi Norio Horiguchi Satoru Kakizaki Motoyasu Kusano Masanobu Yamada | 2016 | World Journal of Clinical Cases2016，4，3： | 2 |
| 6 | Inaccuracy and misjudged fac- tors of Glasgow Coma Scale scores when assessed by inexperiencedphysicians显示文摘 | Jun N Motoyasu Y Tomohiro F | 2011 | Clinical Neurology and Neurosurgery2011，113，5： | 1 |
| 7 | Pilot-scale Casting of Single-crystal Copper Wires by the Ohno Continuous Casting Process显示文摘 | Soda H McLean A Wang Z and Motoyasu G | 1995 | Journal of Materials Science1995，，30： | 1 |
| 8 | Electrical phase-change memory: fundamentals and state of the art 显示文摘 | Motoyasu Terao Takahiro Morikawa Takeo Ohta | 2009 | Japanese Journal of Applied Physics2009，48，1： | 1 |
| 9 | The characteristics of single crystal bismuth wires produced by the Ohno continuous casting process 显示文摘 | Motoyasu G Kadowaki H Soda H McLean A | 1999 | Journal of materials science1999，，34： | 1 |
| 10 | Inaccuracy and misjudged fac- tors of Glasgow Coma Scale scores when assessed by inexperienced physicians显示文摘 | Jun N Motoyasu Y Tomohiro F | 2011 | Clinical Neurology and Neurosurgery2011，113，5： | 1 |
| 11 | Studies of the Solid-liquid Interface Location during Heated Mould Continuous Casting of Metals and Alloys显示文摘 | Soda H McLean A and Motoyasu G | 2005 | International Journal of Cast Metals Research2005，18，3： | 1 |
| 12 | Continuously cast Cu-Al-Ni shape memory wires with a unidirectional morphology显示文摘 | MOTOYASU G KANEKO M SODA H MCLEAN A | 2001 | Metallurgical and Materials Transactions A2001，32，3： | 1 |
| 13 | Noninfarcted myocardium: correlation between dynamic first-pass contrast- enhanced myocardial MR imaging and quantitative coronary angiography显示文摘 | Ishida N Sakuma H Motoyasu M | 2003 | Radiology2003，229，1： | 1 |
| 14 | Annual Periodic Increases in Serum Carcinoembryonic Antigen Concurrent with Ground-Glass Opacity in the Lung: Report of a Case显示文摘 | Tsutomu Sakuma Yumiko Iwata Yoshimichi Ueda Xiu Gu Makoto Sugita Motoyasu Sagawa | 2005 | Surgery Today2005，，10： | 1 |
| 15 | A comparison of long-term anti-inflammatory effect of two ICS/LABA combination inhalers; fix-dosed maintenance therapy with budesonide/formot- erol and salmeterol, fluticasone 显示文摘 | Masayuki Hojo Motoyasu Iikura Junko | 2014 | Allergology international : offi- cial journal of the Japanese Society of Allergology2014，63，1： | 1 |
| 16 | Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings显示文摘 | Tohko Shirota Motoyasu Kusano Osamu Kawamura Tsutomu Horikoshi Masatomo Mori Toshikazu Sekiguchi | 1999 | Journal of Gastroenterology1999，，5： | 1 |
| 17 | Direct measurement of interactions between stimulation-responsive drug delivery vehicles and artifieial muein layers by colloid probe atomic force mieroseopy 显示文摘 | Motoyuki I Motoyasu Y Tadashi T | 2008 | Langmuir2008，24，8： | 1 |
| 18 | Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir显示文摘A 66-year-old, interferon-ineligible, treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C virus genotype 1b began combination therapy with daclatasvir and asunaprevir. On day 14 of treatment, hepatic reserve and renal function deterioration was observed, while his transaminase levels were normal. Both daclatasvir and asunaprevir were discontinued on day 18 of treatment, because the patient complained of dark urine and a rash on his trunk and four limbs. After discontinuing antiviral therapy, the abnormal laboratory finding and clinical manifestations gradually improved, without recurrence. Our case fulfilled the diagnostic criteria of probable drug reaction with eosinophilia and systemic symptom(DRESS) syndrome. Despite the 18-d treatment, sustained virological response 12 was achieved. Based on the clinical course, we concluded that there was a clear cause-and-effect relationship between the treatment and adverse events. To our knowledge, this patient represents the first case of probable DRESS syndrome that includes concomitant deterioration of hepatic reserve and renal function due to combination therapy with daclatasvir and asunaprevir, regardless of normalization of transaminase levels. Our case suggests that we should pay attention not only to the transaminase levels but also to allergic symptoms associated with organ involvement during combination therapy with daclatasvir and asunaprevir. | Takayoshi Suga Ken Sato Yuichi Yamazaki Tatsuya Ohyama Norio Horiguchi Satoru Kakizaki Motoyasu Kusano Masanobu Yamada | 2015 | World Journal of Clinical Cases2015，3，12： | 1 |
| 19 | The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumor显示文摘 | Motoyasu S Matthew DR | 2010 | Molec Cellular Endocrinol2010，321，1： | 1 |
| 20 | Development and evaluation of FSSG: frequency scale for the symptoms of GERD显示文摘 | Motoyasu Kusano Yasuyuki Shimoyama Sayaka Sugimoto Osamu Kawamura Masaki Maeda Keiko Minashi Shiko Kuribayashi Tatsuya Higuchi Hiroaki Zai Kyoko Ino Tsutomu Horikoshi Tadashi Sugiyama Munetoshi Toki Tsuneo Ohwada Masatomo Mori | 2004 | Journal of Gastroenterology2004，，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员